J Parasitol 2005, 91:269–274.PubMedCrossRef 15. Afrin F, Ali N: Adjuvanticity and protective immunity elicited

by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 1997, 65:2371–2377.PubMed 16. Bhowmick S, Ravindran R, Ali N: Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized AZD3965 Th1 response. Vaccine 2007, 25:6544–6556.PubMedCrossRef 17. Bhowmick S, Ravindran R, Ali N: gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani . Infect Immun 2008, 76:1003–1015.PubMedCrossRef 18. Bhowmick S, Ali N: Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS One 2009, 4:e5820.PubMedCrossRef 19. PLX-4720 ic50 McMahon-Pratt D, Alexander J: Does the

Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 2004, FDA-approved Drug Library purchase 201:206–224.PubMedCrossRef 20. Engwerda CR, Murphy ML, Cotterell Sara EJ, Smelt Sara C, Kaye PM: Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani . Eur J Immunol 1998, 28:669–680.PubMedCrossRef 21. Kaye PM, Curry AJ, Blackwell JM: Differential production of Th1 and Th2-derived cytokines does not determine the genetically controlled or vaccine induced rate of

cure in murine visceral leishmaniasis. J Immunol 1991, 146:2763–2770.PubMed 22. Melby PC, Yang J, Zhao W, Perez LE, Cheng J: Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001, 69:4719–4725.PubMedCrossRef 23. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW: Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun pentoxifylline 1994, 62:1058–1063.PubMed 24. Murray HW, Hariprashad J, Coffman RL: Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med 1997, 185:867–874.PubMedCrossRef 25. Satoskar A, Bluethmann H, Alexander J: Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 1995, 63:4894–4899.PubMed 26. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F: Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 2000, 30:2935–2943.PubMedCrossRef 27. Mazumdar T, Anam K, Ali N: A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.